^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DCVAC/OvCa

    i
    Other names: DCVAC/OvCa, dendritic cell vaccine/ovarian cancer
    Associations

    News

    Trials
    Company:
    Sotio
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    almost2years
    An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors. (PubMed, Clin Cancer Res)
    Our findings suggest that while patients with highly infiltrated, "hot" EOCs benefit from chemotherapy, women with "cold" EOCs may instead require DC-based vaccination to jumpstart clinically relevant anticancer immune responses.
    Journal • Tumor Mutational Burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
    |
    TMB-L
    |
    DCVAC/OvCa
    2years
    Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. (PubMed, J Immunother Cancer)
    DCVAC/OvCa and leukapheresis was not associated with significant safety concerns in this trial. DCVAC/OvCa sequential to CT was associated with a statistically significant improvement in PFS in patients undergoing first-line treatment of EOC.
    Clinical • P2 data • Journal
    |
    CD14 (CD14 Molecule)
    |
    carboplatin • paclitaxel • DCVAC/OvCa
    over2years
    VITALIA: DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma (clinicaltrials.gov)
    P3, N=0, Withdrawn, SOTIO a.s. | N=678 --> 0 | Trial completion date: Jul 2027 --> Aug 2021 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2027 --> Aug 2021
    Clinical • Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    DCVAC/OvCa
    3years
    A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care (clinicaltrials.gov)
    P2, N=75, Recruiting, Peking University Third Hospital | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    DCVAC/OvCa
    3years
    A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, Peking University Third Hospital | Trial completion date: Mar 2025 --> Apr 2027 | Trial primary completion date: Mar 2023 --> Oct 2024
    Clinical • Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    DCVAC/OvCa
    3years
    A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care (clinicaltrials.gov)
    P2, N=75, Recruiting, Peking University Third Hospital
    Clinical • New P2 trial
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    DCVAC/OvCa
    4years
    VITALIA: DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma (clinicaltrials.gov)
    P3, N=678, Not yet recruiting, Sotio a.s. | Trial completion date: Mar 2027 --> Jul 2027 | Initiation date: May 2020 --> Sep 2020 | Trial primary completion date: Mar 2027 --> Jul 2027
    Clinical • Trial completion date • Trial initiation date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    DCVAC/OvCa